Ascentage Closes $72 Million B Round for Oncology Drugs

Ascentage Pharma of China completed a $72 million Series B funding, led by SDIC Fund Management, a China state-sponsored investor. Ascentage is a clinical-stage pharma focused on developing small-molecule oncology drugs with apoptosis mechanisms. Yesterday, Ascentage announced its novel Bcl-2/Bcl-XL inhibitor was approved to begin clinical trials in the US, the company's sixth molecule to start clinical development. In 2015, Ascentage raised $15.5 million in initial venture funding. More details.... Share this with colleagues: // //